Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 13
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Ionis Pharmaceuticals Inc
IONS
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$42.47
-1.20
-2.76%
Dern. MÀJ: Oct 13, 12:40 PM
$43.55
-0.12
-0.27%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Ionis Pharmaceuticals Analyst Price Targets - Benzinga
Ionis Pharmaceuticals Analyst Price Targets
Wall Street analyst price targets and consensus rating for Ionis Pharmaceuticals (IONS).
Analyst Ratings News
PRO
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.
Benzinga Newsdesk
PRO
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.
Benzinga Newsdesk
PRO
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.
Benzinga Newsdesk
PRO
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.
Benzinga Newsdesk
PRO
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.
Benzinga Newsdesk
PRO
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.
Benzinga Newsdesk
Créez votre liste de surveillance
GRATUIT : Suivez les actions et les crypto-monnaies avec les meilleures notifications sur Internet
Cliquez ici pour commencer
People Also Watch
AbbVie Inc
NYSE:ABBV
$276.01
-1.82%
Amgen Inc
NASDAQ:AMGN
$415.18
-0.57%
Gilead Sciences Inc
NASDAQ:GILD
$147.6
-1.88%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
$490.06
-3.34%
Moderna Inc
NASDAQ:MRNA
$214.31
0.27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
$752.54
-1.35%
Natera Inc
NASDAQ:NTRA
$395.95
-0.46%
argenx SE
NASDAQ:ARGX
$803.51
-1.08%
Revolution Medicines Inc
NASDAQ:RVMD
$190.87
-1.59%
BeOne Medicines Ltd
NASDAQ:ONC
$350.17
-0.07%
Afficher toutes les 10 entreprises associées
